



GIORNATA STUDIO SULLE PROBLEMATICHE ATTUALI DEL SETTORE LATTIERO-CASEARIO





Facoltà di Medicina Veterinaria, Via dell'Università n. 1, Lodi, Aula Magna
Sabato 1 dicembre 2018

Bacillus cereus: tassonomia, fattori di patogenicità e problematiche nell'uomo

*Prof.ssa Emilia Ghelardi
Dipartimento di Ricerca Traslazionale NTMC,
Università di Pisa*




IL GRUPPO *BACILLUS CEREUS*




- Bastoncelli Gram-positivi, aerobi o aerobi facoltativi, sporigeni
- Ampiamente diffusi nell'ambiente sotto forma di spore
- Specie strettamente correlate a livello genetico ma con diversi ecotipi
- Patogene e non patogene

BACILLUS CEREUS: DIFFUSIONE E ISOLAMENTO





BACILLUS CEREUS: MOTILITÀ

- Mobile per flagelli peritrichi




- Sciama su superfici solide o semisolide



Cellula swarm

Maggiore adesività a superfici biotiche e abiotiche
Incrementata sintesi e secrezione di alcuni fattori di virulenza


BACILLUS CEREUS: VIRULENZA





- Due complessi enterotossici:
emolisina BL (HBL) e enterotossina non-emolitica (NHE)
- Varie emolisine/citolisine:
HlyI (cereolisina O); HlyII; HlyIII, HlyIV(citossina K CytK)
- Enterotossine minori (Ent FM; Ent Bcet...)
- Diverse **fosfolipasi-C**
- Collagenasi
- Tossina **emetica**

EMOLISINA BL HBL


- Prodotta da circa il 60% dei ceppi di *B. cereus*



- Attività
emolitica → 
- dermonecrotica
- incremento permeabilità vascolare
- necrosi oculare
- enterotossica** → 


ENTEROTOSSINA NON EMOLITICA NHE

- Prodotta da circa il 100% dei ceppi di *B. cereus*



- Attività enterotossica?
apoptosi (Liu et al., Cell Microbiol, 2016)

Nhe





HLY I, HLY II, HLY IV

Hly I Cereolisina O

Tossina termolabile la cui attività è inibita dal colesterolo e che viene neutralizzata da un siero anti streptolisina-O

Hly II

Azione simile alla α -tossina di *S. aureus*




Hly IV CytK

Grave epidemia Francia 1998
NVH 391-98 (*B. cytotoxicus*)
CytK-1 e CytK-2
Tossica per cellule epiteliali (Caco-2 e Vero) ed emolitica
Simile alla leucocidina di *S. aureus*


FOSFOLIPASI C

Attive su diversi tipi cellulari


Ruolo determinante nelle infezioni sistemiche sostenute da *B. cereus*



(Celandroni et al., FEMS Microbiol Lett 2014)




TOSSINA EMETICA CEREULIDE



Dodecadepsipeptide (*D*-*O*-Leu-*D*-Ala-*L*-*O*-Val-*L*-Val)₃ sintetizzato da un complesso di sintetasi peptidiche non-ribosomiali (NRPS) dette cereulide sintetasi e codificate dal cluster di geni *ces*


Estremamente termostabile (120°C per 90 min), stabile ad un ampio range di pH (2-11) e resistente agli enzimi proteolitici

- Agisce come ionoforo del K⁺
- Alterazione del gradiente elettrochimico
- Alterazione mitocondriale





TOSSINA EMETICA CEREULIDE

- a** cereulide: $[(D-O\text{-Leu}\text{-D-Ala}\text{-L-O-Val-L-Val})_2(D-O\text{-Leu}\text{-D-Ala}\text{-L-O-Val-L-Val})]$
isocereulide A: $[(D-O\text{-Leu}\text{-D-Ala}\text{-L-O-Val-L-Val})_2(D-O\text{-Leu}\text{-D-Ala}\text{-L-O-}\underline{\text{Leu}}\text{-L-Val})]$
isocereulide B: $[(D-O\text{-Leu}\text{-D-Ala}\text{-L-O-Val-L-Val})_2(\underline{D-O-Val}\text{-D-Ala}\text{-L-O-Val-L-Val})]$
isocereulide C: $[(D-O\text{-Leu}\text{-D-Ala}\text{-L-O-Val-L-Val})_2(D-O\text{-Leu}\text{-D-Ser}\text{-L-O-Val-L-Val})]$
isocereulide D: $[(D-O\text{-Leu}\text{-D-Ala}\text{-L-O-Val-L-Val})_2(D-O\text{-Leu}\text{-D-Ala}\text{-L-O-Val-L-Ala})]$
isocereulide E: $[(D-O\text{-Leu}\text{-D-Ala}\text{-L-O-Val-L-Val})_2(D-O\text{-Leu}\text{-D-Ala}\text{-D-O-Ile-D-Ala})]$
isocereulide F: $[(D-O\text{-Leu}\text{-D-Ala}\text{-L-O-Val-L-Val})_2(\underline{L-O-Val-L-Val-L-O-Val-L-Val})]$
isocereulide G: $[(D-O\text{-Leu}\text{-D-Ala}\text{-L-O-Val-L-Val})_2(\underline{L-O-Val-L-Val-D-O-Leu-D-Ala})]$



EFFETTO EMETICO DELLA CEREULIDE

Dipendente dalla stimolazione dei recettori 5-HT_3 sui neuroni vagali afferenti



MALATTIE NON GASTROINTESTINALI

Varietà di infezioni locali e sistemiche

Infezioni cutanee, batteriemie, meningitis, endoftalmiti.....

Species	Total samples(n. of strains)	Deep body sites(n. of strains)	Superficial body sites(n. of strains)
<i>B. cereus</i>	33.3% (25)	32.0% (16)	36.0% (9)
<i>B. pumilus</i>	18.7% (14)	22.0% (11)	12.0% (3)
<i>B. subtilis</i>	14.7% (11)	10.0% (5)	24.0% (6)
<i>B. licheniformis</i>	6.7% (5)	10.0% (5)	0.0% (0)
<i>B. megaterium</i>	6.7% (5)	6.0% (3)	8.0% (2)
<i>B. simplex</i>	6.7% (5)	6.0% (3)	8.0% (2)
<i>B. mycoides</i>	4.0% (3)	2.0% (1)	8.0% (2)
<i>B. flexus</i>	4.0% (3)	4.0% (2)	4.0% (1)
<i>P. glucanolyticus</i>	2.7% (2)	4.0% (2)	0.0% (0)
<i>P. amyloolyticus</i>	1.3% (1)	2.0% (1)	0.0% (0)
<i>P. laetus</i>	1.3% (1)	2.0% (1)	0.0% (0)
Total	100% (75)	100% (50)	100% (25)

doi:10.1371/journal.pone.0152831.t002

(Celandroni et al., PLOSone 2016)


MALATTIE NON GASTROINTESTINALI

Species(n. of strains)	Toxins/enzymes					Virulence genes				
	Hemolysins	HBL	PC-PLC	Proteases	<i>plca</i>	<i>sph</i>	<i>cytK</i>	<i>nheA</i>	<i>nheB</i>	<i>nheC</i>
<i>B. cereus</i> (25)	100	84.0	88.0	56.0	40.40.0	52.0	24.0	60.0	56.0	56.0
<i>B. pumilus</i> (14)	92.8	0.0	0.0	100	0.0	0.0	0.0	71.4	50.8	57.1
<i>B. subtilis</i> (11)	0.0	0.0	0.0	100	0.0	0.0	0.0	18.2	0.0	0.0
<i>B. licheniformis</i> (5)	0.0	0.0	0.0	60.0	0.0	0.0	0.0	0.0	0.0	0.0
<i>B. megaterium</i> (5)	0.0	0.0	0.0	100	0.0	0.0	0.0	20.0	0.0	0.0
<i>B. simplex</i> (5)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
<i>B. mycoides</i> (3)	0.0	0.0	0.0	33.3	0.0	0.0	0.0	0.0	0.0	0.0
<i>B. flexus</i> (3)	0.0	0.0	0.0	100	0.0	0.0	0.0	33.3	0.0	33.3
<i>P. glucanolyticus</i> (2)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
<i>P. amyloolyticus</i> (1)	0.0	0.0	0.0	100	0.0	0.0	0.0	100	0.0	100
<i>P. laetus</i> (1)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total (75)	50.6	28.0	29.3	69.3	13.3	17.3	8.0	40.0	28.0	32.0

doi:10.1371/journal.pone.0152831.t004

(Celandroni et al., PLOSone 2016)

SINDROME DIARROICA



DIARRHEA

Diarrheal syndrome is due to the **production of heat labile enterotoxins during growth of vegetative cells in the small intestine** of the host and the **infective dose is 10^4 – 10^9 cells per gram of food**. This syndrome is mild and primarily manifested by **abdominal cramps and diarrhea** following an **incubation period of 8 to 16 h** and lasting for 6 to 12 h. Diarrhea may be mild or profuse and watery.

SINDROME EMETICA



The emetic syndrome is more severe and acute than diarrheal syndrome and is referred to as “short-incubation” or emetic form of the disease. Emetic syndrome is characterized by **nausea and vomiting and abdominal cramps**. The toxin responsible for this syndrome is a small cyclic heat-stable peptide which causes vomiting after **1 to 6 h of ingestion (average 2 to 5 h)**. The toxin **is preformed and indigested with food**. In emetic type of illness, the dose is about 10^5 – 10^8 cells per gram in order to produce sufficient toxin. It resembles *Staphylococcus aureus* food poisoning in its symptoms and incubation period.

Bacillus cereus: a flexible human pathogen

